^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SENTI-401

    i
    Other names: SENTI-401, Logic Gated Allogeneic CAR-NK Cell Therapy
    Associations

    News

    Trials
    Company:
    Senti Bio
    Drug class:
    CEA inhibitor, CEACAM5 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2years
    SENTI-401, an Allogeneic Logic-Gated and Multi-Armed CAR-NK Cell Therapy for the Treatment of CEA-Expressing Solid Tumors with Enhanced Selectivity and Efficacy (SITC 2022)
    Similarly, we optimized gene-circuits to confer resistance to the immunosuppressive effects of TGFb; anti-CEA CAR-NK cells armed with TGFb-blocking constructs sustained target-cell killing in the continuous presence of TGFb. Conclusions SENTI-401 incorporates NOT-Gating and Multi-Arming gene-circuits into CAR-NK cells in order to improve the therapeutic window and efficacy of CEA-targeting cell-therapies for the treatment of solid tumors.
    Clinical
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • IL15 (Interleukin 15) • IL21 (Interleukin 21)
    |
    CEACAM5 expression
    |
    SENTI-401